Review Article

Use of Contrast-Enhanced Ultrasound in Carotid Atherosclerotic Disease: Limits and Perspectives

Gianfranco Varetto, Lorenzo Gibello, Claudio Castagno, Simone Quaglino, Matteo Ripepi, Emilio Benintende, Andrea Gattuso, Paolo Garneri, Stefano Zan, Giacomo Capaldi, Ugo Bertoldo, and Pietro Rispoli

Division of Vascular Surgery, Department of Surgical Sciences, University of Turin, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Molinette Corso Bramante 88, 10126 Torino, Italy

Correspondence should be addressed to Pietro Rispoli; pietro.rispoli@unito.it

Received 14 August 2014; Revised 6 November 2014; Accepted 11 November 2014

Academic Editor: Marco Francone

Copyright © Gianfranco Varetto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Contrast-enhanced ultrasound (CEUS) has recently become one of the most versatile and powerful diagnostic tools in vascular surgery. One of the most interesting fields of application of this technique is the study of the carotid atherosclerotic plaque vascularization and its correlation with neurological symptoms (transient ischemic attack, minor stroke, and major stroke) and with the characteristics of the “vulnerable plaque” (surface ulceration, hypoechoic plaques, intraplaque hemorrhage, thinner fibrous cap, and carotid plaque neovascularization at histopathological analysis of the sample after surgical removal). The purpose of this review is to collect all the original studies available in literature (24 studies with 1356 patients enrolled) and to discuss the state of the art, limits, and future perspectives of CEUS analysis. The results of this work confirm the reliability of this imaging study for the detection of plaques with high risk of embolization; however, a shared, user-friendly protocol of imaging analysis is not available yet. The definition of this operative protocol becomes mandatory in order to compare results from different centers and to validate a cerebrovascular risk stratification of the carotid atherosclerotic lesions evaluated with CEUS.

1. Introduction

CEUS represents one of the major breakthroughs in the field of diagnostic ultrasound. In fact, the contrast medium, injected intravenously, passes through the vascular region of interest generating an enhanced ultrasound signal that allows a better morphological and functional imaging resolution [1]. Moreover the simplicity and rapidity of execution even at the patient’s bedside encouraged its application for different vascular purposes: the definition of the degree of stenosis and plaque surface (i.e., higher sensitivity for plaque ulceration or near-occlusion stenosis), the diagnosis of in-stent restenosis, the detection of type II endoleaks (even those with low flow rate), the assessment of organ perfusion (i.e., kidney transplantation), or the assessment of tumor perfusion (important prognostic parameter in metastatic tumors) [2]. Another interesting field of application of CEUS is the study of the carotid atherosclerotic plaque vascularization and its correlation with cerebrovascular neurological events (stroke, transient ischemic attack). Data available from large study population in literature reveal a 5-year risk for ipsilateral stroke of 5% of patients with asymptomatic carotid artery stenosis of 70% or greater [3–5]. The traditional parameters for the description of a carotid atherosclerotic plaque (degree of stenosis, systolic peak velocity) are insufficient predictors of the risk of embolization while the vascularization of the atherosclerotic plaque, evaluated with CEUS, is correlated with a more accurate “qualitative” analysis of the carotid disease [2]. Differently from what happens for the other fields of application of CEUS, the study of the carotid plaque vascularization requires a more precise quantification of the enhancement which is obtained by a visual or semiautomated method [6]. The objective of this review is to analyze the application of CEUS for the study of plaque microvascularization in carotid atherosclerosis and to define the strengths and limits of this technique.
2. Correlation between Plaque Microvascularization and Potentially Symptomatic Atherosclerotic Lesions

The inflammatory etiopathogenesis of atherosclerosis has been widely demonstrated in several animal models and later confirmed in human models [7]. In particular at the level of flow turbulence along the vascular tree (vessel bifurcation), the subintimal deposition of cholesterol and oxidized lipoproteins generates an inflammatory response with the recruitment of white blood cells, primarily macrophages, and the production of cytokines and enzymes. Among different cellular responses to the inflammatory stimulus there is the liberation from the smooth muscles cells of vascular endothelial growth factor (VEGF) with the consequent activation of neoangiogenesis of the vessel wall (Figure 1). The newly formed vessels inside the atherosclerotic plaque however are immature and leaky due to reduced gap junctions, thus serving as a port of entry for other inflammatory cells, lipids, and even red blood cells, which contribute to plaque growth. In the same contest macrophages produce metalloproteinases, like MMP-9 and other collagenases that destroy the connective fibrous tissue, thus stimulating the neovessels growth [8]. All these plaque changes lead to a vulnerable atherosclerotic plaque [7]. It is common experience in clinical practice that irregular, ulcerated plaque surfaces, lipid necrotic core, thin fibrous cap, anechoic-hypoechoic appearance, and intraplaque neovessels characterize potentially unstable atherosclerotic lesions with high risk of embolization and thrombosis. However, it is common experience that not all the atherosclerotic lesions behave in the same way. In fact some of them react to the inflammation stimulus with the precipitation of calcium salts (calcific plaques) and others with the simple transformation of muscular cells into connective cells (fibrous plaques). The exact mechanism of differentiation of the plaque is still partially unknown but some factors, such as genetic predisposition, uncontrolled risk factors like smoke, diabetes mellitus, hypertension, and dyslipidemia, may influence the process.

3. Methods

3.1 Search Strategy. This review included all available original studies reporting the use of CEUS for the evaluation of the vascularization of the carotid atherosclerotic plaque and its correlation with ipsilateral neurological events and with other indicators of plaque “vulnerability”. Data were collected from the online MEDLINE database in July 2014 using PubMed (National Center for Biotechnology Information, US National Library of Medicine, Bethesda, MD). The search strategy included the words “carotid,” “atherosclerosis,” and “contrast-enhanced.” No time restriction for publication date was used. The search was restricted to articles published in English and to studies in humans.

3.2 Study Selection, Data Extraction, and Analysis. All abstracts were reviewed online and articles meeting the inclusion criteria were identified and downloaded for data extraction. In addition, a manual search of the reference lists of the identified studies was performed, and references were evaluated. Data collected from the selected studies were registered into a specific database and analyzed with Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA). Despite the heterogeneity of the studies it was possible to create different macrocategories of correlation between the degree of the enhancement of the atherosclerotic lesion and neurological symptoms (transient ischemic attack, minor stroke, and major stroke) or other plaque characteristics: histology (quantification of the microvascularization of the carotid plaque after surgical removal), echogenicity with Doppler ultrasound (evaluated with a visual assessment according to the Gray Weale scale—GW scale—or with a software analysis according to the Gray Scale Median—GSM), signs
of microembolization, or plaque instability (plaque surface ulceration, cerebral ipsilateral microembolization detected with transcranial Doppler ultrasonography in absence of other possible causes).

4. Results
The search identified 24 original studies (100% single-center studies) suitable for revision from 2007 to 2014 (Table 1) [9–32]. The review population consisted of 1356 patients with carotid atherosclerosis examined with CEUS; 946 patients (70%) were asymptomatic. In 19 studies (76%) the contrast medium used was SonoVue (Bracco, Altana Pharma, Konstanz, Germany), 2 studies (7%) used Definity (Bristol-Myers Squib Medical Imaging, Billerica, Massachusetts), and 3 studies (7%) used Optison (GE Healthcare, Little Chalfont, Buckinghamshire, UK). CEUS imaging of the carotid artery was performed using linear array vascular probe with transmission frequencies ranging from 3 to 15 MHz and mechanical index ranging from 0.06 to 1.4. The analysis of the contrast enhancement was performed with a semiautomated software in 16 studies (often home-made software). In 15 studies, a visual classification of the plaque enhancement was performed by two different operators (nonuniformity in scoring methods). In 7 studies (29%) plaques were evaluated with both methods. The correlation between data obtained with CEUS and histopathologic results was performed in 12 studies (50%, 433 patients) and all the studies found a statistically significant correlation: plaques with higher enhancement have a highly significant vascularization of the plaque. Ten studies (41%, 578 patients) evaluated the correlation between CEUS images and the presence of ipsilateral neurological symptoms: in three cases (30%, 91 patients) results did not reach statistical significance to demonstrate that plaques with greater contrast enhancement are more frequently related to clinical symptoms. In 7 studies (29%, 331 patients) CEUS analysis was compared to the plaque echogenicity; all the studies found a statistically significant correlation: plaques with high contrast enhancement have a low echogenicity. Six studies (25%, 351 patients) compared CEUS with other indicators of “vulnerable plaque” (surface ulceration, cerebral microembolization detected with transcranial Doppler); all the studies found a statistically significant correlation: the increased vascularization of carotid atherosclerotic plaques evaluated with CEUS is more frequently related to cerebral microembolization or surface ulceration. One study (4%, 143 patients) compared CEUS to the patient’s gender with a statistically significant correlation \( P = 0.03 \): women have a higher contrast enhancement of the carotid plaque.

5. Discussion
5.1. Correlation between CEUS and the Characteristics of the Vulnerable Carotid Plaque. Data collected from an overall review population of 1356 patients demonstrate that information obtained by CEUS imaging is strictly dependent not only on the plaque microvascularization (histological analysis) but also correlated to the plaque echogenicity, the surface ulceration, and the intraplaque hemorrhage (100% agreement among the studies). All these parameters together define an atherosclerotic plaque with high risk of embolization. In detail plaques with low echogenicity, surface ulceration, and histopathological findings of intraplaque hemorrhage have a greater enhancement with CEUS compared to calcific or fibrous plaques. Results on the correlation between CEUS and clinical neurological symptoms do not reach statistical evidence in all the studies; in fact 7 studies (487 patients) established a significant relationship between the two parameters while 3 studies (91 patients) did not reach statistical significance. The reason of this finding is not completely clear: according to the general agreement among the studies on the reliability of CEUS for the detection of a “vulnerable plaque,” it would be logical to expect also a correlation with neurological symptoms. However these results could be partially explained with the low single-center study population or with silent neurological damage among asymptomatic patients. From the results obtained, CEUS appears to be one of the most reliable imaging studies for the detection of atherosclerotic lesions with high risk of embolization because of the correlation with every single expression of the plaque instability (intraplaque hemorrhage, surface ulceration, low echogenicity, and plaque microvascularization). In current literature there is not a specific indication for the “suitable patient” for CEUS analysis; however, the strong relationship between the plaque enhancement and the echogenicity of the carotid plaque led some authors to select a subgroup of the population (asymptomatic with an hypoechoic carotid plaque) that would benefit most from this investigation [19].

5.2. CEUS Imaging Analysis. The acquisition of CEUS images was made with different ultrasound hardware and different presets (i.e., mechanical index, linear probes). The majority of the studies used a linear probe with frequencies between 3 MHz and 10 MHz. The mechanical index as well differs among the studies; however, many authors agree that a lower mechanical index (between 0.06 and 0.2) is preferred to obtain a better image resolution and to reduce the risk of rupture of the microbubbles of contrast agent [33].

The analysis of the images obtained with CEUS can be performed in two ways: the semiautomated method and the visual score of the enhancement; often they are used together. The semiautomated assessment is performed with a software (usually a home-made software) that analyzes the variation of enhancement intensity over time in a region of interest (ROI). The timing of the analysis differs among the studies (i.e., evaluation of maximum signal intensity [19], evaluation of the late phase of contrast enhancement [23]) as well as the unit of measurements (i.e., dB-enhanced [20], percentage ratio between area of plaque captation and silent areas [19]). Strengths of this method are a better reproducibility over time with the same software and presetting and the reduction of the operator-related bias. Some limits of this method are the need of reproprocessing the images (not immediate result) and the need of a motion tracking algorithm (not simple implementation) to reduce errors of interpretation on the luminal side of the plaque. On the other hand, the visual
| Author            | Year | Number of patients | Symptomatic | Asymptomatic | Histology | Contrast agent | Ultrasound apparatus | Vascular probe | Mechanical index | CEUS analysis | Results |
|-------------------|------|--------------------|-------------|--------------|-----------|----------------|----------------------|----------------|------------------|--------------|---------|
| Li et al.         | 2014 | 17                 | 13          | 4            | 1         | SonoVue        | Philips iU-22 system | L-9-3          | 0.07             | 1            | 1       | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hjelmgren et al.  | 2014 | 13                 | 7           | 6            | 0         | SonoVue       | Siemens S2000 system | L-9-4          | 0.06             | 1            | 1       | 0   | 0.05 | 0.01 | 0 | 0 | 0 | 0.001 |
| Kim et al.        | 2014 | 89                 | 0           | 89           | 1         | SonoVue       | Acuson Sequoia 512 | L-15-8         | 0.19             | 0            | 1       | 0   | 0.021 | 0 | 0 | 0 | 0 |
| van den Oord et al. | 2014 | 143                | 0           | 143          | 0         | SonoVue       | Philips iU-22 system | L-9-3          | 0.06–0.08       | 1            | 1       | 0   | 0   | 0   | 0 | 0 | 0.03 | 0 |
| Müller et al.     | 2014 | 33                 | 17          | 16           | 1         | SonoVue       | Arthres system     | nm             | nm              | 1            | 1       | 0   | 0.01 | Not significant | 0 | 0 | 0 | 0.02 |
| Vavuranakis et al. | 2013 | 14                 | 0           | 14           | 1         | SonoVue       | Acuson Sequoia 512 | L-15-8         | nm              | 1            | 0       | 0   | 0.02 | 0   | 0 | 0 | 0 | 0 |
| Ritter et al.     | 2013 | 41                 | 41          | 0            | 0         | SonoVue       | GE Logiq 7 system  | L-9-3          | nm              | 0            | 0       | 0   | 0   | 0   | 0.02 | 0 | 0 |
| Hjelmgren et al.  | 2013 | 52                 | 10          | 42           | 0         | SonoVue       | Siemens S2000 system | L-9-4          | 0.06             | 1            | 0       | 0   | Not significant | 0.02 | 0 | 0 | 0 |
| van den Oord et al. | 2013 | 69                 | 0           | 69           | 0         | SonoVue       | Philips iU-22 system | L-9-3          | 0.06–0.08       | 1            | 1       | 0   | 0   | 0   | 0.05 | 0 | 0 |
| Zhou et al.       | 2013 | 46                 | 24          | 22           | 0         | SonoVue       | Acuson Sequoia 512 | L-2            | 0.07             | 0            | 1       | 0   | Not significant | 0 | 0.05 | 0 | 0 |
| Varetto et al.    | 2012 | 51                 | 12          | 39           | 1         | SonoVue       | Esaote MyLab Gold system | L-9-2          | nm              | 1            | 0       | 0.001 | 0.01 | 0.02 | 0 | 0 | 0 |
| Faggioli et al.   | 2011 | 22                 | 7           | 15           | 1         | SonoVue       | Philips iU-22 system | L-9-3          | 0.13             | 1            | 0       | 0   | 0.03 | 0.006 | 0 | 0 | 0 | 0 |
| Hoogi et al.      | 2011 | 27                 | 8           | 19           | 1         | SonoVue       | Philips iU-22 system | L-8-4          | 1                | 0            | 0       | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Shalhoub et al.   | 2011 | 31                 | 16          | 15           | 1         | SonoVue       | Philips iU-22 system | L-12-5         | 0.34             | 1            | 0       | 0.004 | 0 | 0 | 0 | 0 | 0 |
| Owen et al.       | 2010 | 37                 | 16          | 21           | 0         | SonoVue       | Philips iU-22 system | L-12-5         | 0.34             | 1            | 0       | 0.005 | 0 | 0 | 0 | 0 | 0 | 0 |
| Author        | Year | Number of patients | Symptomatic | Asymptomatic | Histology | Contrast agent | Ultrasound apparatus | Vascular probe | Mechanical index | CEUS analysis | Results |
|--------------|------|--------------------|-------------|--------------|-----------|---------------|---------------------|----------------|----------------|---------------|---------|
| Huang et al.[24] | 2010 | 183                | 86          | 97           | 0         | SonoVue       | Acuson Sequoia S12 Siemens system | L 15-8        | 0.35           | 1             | 1       |
| Staub et al.[25] | 2010 | 147                | 17          | 130          | 0         | Definity      | ATL HDI 5000 Philips system | L 7-4         | 0.06–0.1       | 0             | 1       |
| Giannoni et al.[26] | 2009 | 77                 | 64          | 9            | 1         | SonoVue       | Acuson Sequoia S12 Siemens system | L 9-3         | 0.4–1.4        | >0.05         | 0.001   |
| Magnoni et al.[27] | 2009 | 25                 | 0           | 25           | 0         | Optison       | GE Vivid 7 system | L 7           | 0.08–0.1       | 0             | 1       |
| Xiong et al.[28] | 2009 | 104                | 35          | 69           | 0         | SonoVue       | GE Logiq 9 system | L 9-3         | 0.13           | 1             | 0       |
| Huang et al.[29] | 2008 | 63                 | 0           | 63           | 0         | SonoVue       | Acuson Sequoia S12 Siemens system | L 15-8        | 0.35           | 1             | 0       |
| Coli et al.[30] | 2008 | 32                 | 28          | 4            | 1         | Optison       | GE Vivid 7 system | L 7           | 0.08–0.1       | 0             | 1       |
| Vicenzini et al.[31] | 2007 | 23                 | 0           | 23           | 1         | SonoVue       | Acuson Sequoia S12 Siemens system | L 6-15        | 0.4–1.4        | >0.05         | 0       |
| Shah et al.[32] | 2007 | 17                 | 5           | 12           | 1         | Optison       | ATL HDI 5000 Philips system | L 7-4         | 0.06–0.1       | 0             | 1       |
| Total        |      | 1356               | 406         | 946          | 12        |               |                     | 16            | 15             |               |         |
score allows a direct interpretation of the CEUS examination (easier applicability in a clinical setting) but with an increased risk of operator-related bias and less accurate confrontation of the results obtained. Moreover a univocal visual scale is still not defined. Currently no data are available on the superiority of the semiautomated analysis compared to the visual assessment for CEUS. From the data collected in literature it becomes mandatory to create a generally shared operative protocol for the interpretation of CEUS results in order to compare experiences from different centers.

5.3. Tolerability of CEUS. The contrast medium injected intravenously consists of microbubbles filled with gasses (air or high molecular weight gasses) and it has been shown to have a good safety profile. In literature the three most common side effects observed in clinical trials were headache (2.3%), injection site pain (1.4%), and injection site bruising, burning, or paresthesia (1.7%) [34]. Among the studies evaluated in this review, 19 used SonoVue (Bracco), 3 used Optison (GE Healthcare), and 2 studies performed CEUS with Definity (Bristol-Myers). None of the studies reported severe side effects, procedural complication, or anaphylactic reactions to the contrast medium.

5.4. Limits and Future Perspectives of CEUS for the Study of Carotid Atherosclerosis. Despite the excellent results described above, some limits are still evident. Firstly CEUS remains an operator dependent imaging technique; for this reason the creation of a common semiautomated software for the image elaboration could increase the reproducibility and the homogeneity among different operators. Moreover the sensibility of CEUS decreases in heavy calcified plaques with important acoustic shadow. Lastly the bidimensional analysis of the plaque enhancement assumes that the longitudinal cross section of the plaque analyzed is representative of the whole carotid plaque. For this reason it could be interesting to apply the emerging technique of 3D and 4D Doppler ultrasonography to CEUS for a global evaluation of the carotid atherosclerotic lesion.

6. Conclusion

This review confirms the great potential of CEUS for the detection of carotid atherosclerotic plaques with high risk of embolization. However the different procedures used for the analysis of the contrast enhancement limit the possibility to compare results from different centers. The creation of a common, well-established, user-friendly, and operative protocol is essential to overcome this limit to create multicentric studies in order to define a cerebrovascular risk stratification with accurate enhancement cut-offs.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] R. Badea and L. Ciobanu, “Contrast enhanced and doppler ultrasonography in the characterization of the microcirculation. Expectancies and performances,” Medical Ultrasonography, vol. 14, no. 4, pp. 307–313, 2012.
[2] D. Staub, S. Partovi, S. Imfeld et al., “Novel applications of contrast-enhanced ultrasound imaging in vascular medicine,” Vasa, vol. 42, no. 1, pp. 17–31, 2013.
[3] D. Jonas, C. Feltner, and H. Amick, “Screening for asymptomatic carotid artery stenosis: a systematic review and meta-analysis for the U.S. preventive services task force,” Annals of Internal Medicine, vol. 161, no. 5, pp. 336–346, 2014.
[4] A. Nicolaides, S. Kakkos, E. Kyriacou et al., “Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification,” Journal of Vascular Surgery, vol. 52, no. 6, pp. 1486–1496, 2010.
[5] S. K. Kakkos, M. B. Griffin, A. N. Nicolaides et al., “The size of juxtaluminal hypoechoic area in ultrasound images of asymptomatic carotid plaques predicts the occurrence of stroke,” Journal of Vascular Surgery, vol. 57, no. 3, pp. 609.e1–618.e1, 2013.
[6] G. L. ten Kate, S. C. H. van den Oord, E. J. G. Sijbrands et al., “Current status and future developments of contrast-enhanced ultrasound of carotid atherosclerosis,” Journal of Vascular Surgery, vol. 57, no. 2, pp. 539–546, 2013.
[7] A. C. Langheinrich, M. Kampschulte, T. Buch, and R. M. Bohle, “Vasa vasorum and atherosclerosis—quid novit?” Thrombosis and Haemostasis, vol. 97, no. 6, pp. 873–879, 2007.
[8] H. Nagase, R. Visse, and G. Murphy, “Structure and function of matrix metalloproteinases and TIMPs,” Cardiovascular Research, vol. 69, no. 3, pp. 562–573, 2006.
[9] C. Li, W. He, D. Guo et al., “Quantification of carotid plaque neovascularization using contrast-enhanced ultrasound with histopathologic validation,” Ultrasound in Medicine and Biology, vol. 40, pp. 1827–1833, 2014.
[10] O. Hjelmgren, L. Johansson, U. Prahl, C. Schmidt, J. Fredén-Lindqvist, and G. M. L. Bergström, “A study of plaque vascularization and inflammation using quantitative contrast-enhanced US and PET/CT,” European Journal of Radiology, vol. 83, no. 7, pp. 1184–1189, 2014.
[11] H. S. Kim, J. S. Woo, B. Y. Kim et al., “Biochemical and clinical correlation of intraplaque neovascularization using contrast-enhanced ultrasound of the carotid artery,” Atherosclerosis, vol. 233, no. 2, pp. 579–583, 2014.
[12] S. C. H. van den Oord, J. van der Burg, Z. Akkus et al., “Impact of gender on the density of intraplaque neovascularization: a quantitative contrast-enhanced ultrasound study,” Atherosclerosis, vol. 233, no. 2, pp. 461–466, 2014.
[13] H. Müller, A. Viaccoz, I. Kuzmanovic et al., “Contrast-enhanced ultrasound imaging of carotid plaque neo-vascularization: accuracy of visual analysis,” Ultrasound in Medicine & Biology, vol. 40, no. 1, pp. 18–24, 2014.
[14] M. Vavuranakis, F. Sigala, D. A. Vrachatis et al., “Quantitative analysis of carotid plaque vasa vasorum by CEUS and correlation with histology after endarterectomy,” Vasa, vol. 42, no. 3, pp. 184–195, 2013.
[15] M. A. Ritter, K. Theismann, M. Schmiedel, E. B. Ringelstein, and R. Dittrich, “Vascularization of carotid plaque in recently symptomatic patients is associated with the occurrence of transcranial microembolic signals,” European Journal of Neurology, vol. 20, no. 8, pp. 1218–1221, 2013.
[16] O. Hjelmgren, P. Holdfeldt, L. Johansson et al., “Identification of vascularised carotid plaques using a standardised and reproducible technique to measure ultrasound contrast uptake,” *European Journal of Vascular and Endovascular Surgery*, vol. 46, no. 1, pp. 21–28, 2013.

[17] S. C. H. van den Oord, Z. Akkus, J. E. Roeters van Lennep et al., “Assessment of subclinical atherosclerosis and intraplaque neovascularization using quantitative contrast-enhanced ultrasound in patients with familial hypercholesterolemia,” *Atherosclerosis*, vol. 231, no. 1, pp. 107–113, 2013.

[18] Y. Zhou, Y. Xing, Y. Li et al., “An assessment of the vulnerability of carotid plaques: a comparative study between intraplaque neovascularization and plaque echogenicity,” *BMC Medical Imaging*, vol. 13, article 13, 2013.

[19] G. Varetto, L. Gibello, L. Bergamasco et al., “Contrast enhanced ultrasound in atherosclerotic carotid artery disease,” *International Angiology*, vol. 31, no. 6, pp. 565–571, 2012.

[20] G. L. Faggioli, R. Pini, R. Mauro et al., “Identification of carotid “Vulnerable Plaque” by contrast-enhanced ultrasonography: correlation with plaque histology, symptoms and cerebral computed tomography,” *European Journal of Vascular and Endovascular Surgery*, vol. 41, no. 2, pp. 238–248, 2011.

[21] A. Hoogi, D. Adam, A. Hoffman, H. Kerner, S. Reisner, and D. Gaitini, “Carotid plaque vulnerability: quantification of neovascularization on contrast-enhanced ultrasound with histopathologic correlation,” *American Journal of Roentgenology*, vol. 196, no. 2, pp. 431–436, 2011.

[22] J. Shalhoub, C. Monaco, D. R. J. Owen et al., “Late-phase contrast-enhanced ultrasound reflects biological features of instability in human carotid atherosclerosis,” *Stroke*, vol. 42, no. 12, pp. 3634–3636, 2011.

[23] D. R. Owen, J. Shalhoub, S. Miller et al., “Inflammation within carotid atherosclerotic plaque: assessment with late-phase contrast-enhanced US,” *Radiology*, vol. 255, no. 2, pp. 638–644, 2010.

[24] P. Huang, C. Chen, W. Aronow et al., “Assessment of neovascularization within carotid plaques in patients with ischemic stroke,” *World Journal of Cardiology*, vol. 26, pp. 89–97, 2010.

[25] D. Staub, M. B. Patel, A. Tibrewala et al., “Vasa vasorum and plaque neovascularization on contrast-enhanced carotid ultrasound imaging correlates with cardiovascular disease and past cardiovascular events,” *Stroke*, vol. 41, no. 1, pp. 41–47, 2010.

[26] M. F. Giannoni, E. Vicenzini, M. Citone et al., “Contrast carotid ultrasound for the detection of unstable plaques with neoangiogenesis: a pilot study,” *European Journal of Vascular and Endovascular Surgery*, vol. 37, no. 6, pp. 722–727, 2009.

[27] M. Magnoni, S. Coli, M. M. Marrocco-Trischitta et al., “Contrast-enhanced ultrasound imaging of periadventitial vasa vasorum in human carotid arteries,” *European Journal of Echocardiography*, vol. 10, no. 2, pp. 260–264, 2009.

[28] L. Xiong, Y.-B. Deng, Y. Zhu, Y.-N. Liu, and X.-J. Bi, “Correlation of carotid plaque neovascularization detected by using contrast-enhanced US with clinical symptoms,” *Radiology*, vol. 251, no. 2, pp. 583–589, 2009.

[29] P.-T. Huang, F.-G. Huang, C.-P. Zou et al., “Contrast-enhanced sonographic characteristics of neovascularization in carotid atherosclerotic plaques,” *Journal of Clinical Ultrasound*, vol. 36, no. 6, pp. 346–351, 2008.

[30] S. Coli, M. Magnoni, G. Sangiorgi et al., “Contrast enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries. Correlation with histology and plaque echogenicity,” *Journal of the American College of Cardiology*, vol. 52, no. 3, pp. 223–230, 2008.

[31] E. Vicenzini, M. F. Giannoni, F. Puccinelli et al., “Detection of carotid adventitial vasa vasorum and plaque vascularization with ultrasound cadence contrast pulse sequencing technique and echo-contrast agent,” *Stroke*, vol. 38, no. 10, pp. 2841–2843, 2007.

[32] F. Shah, P. Balan, M. Weinberg et al., “Contrast-enhanced ultrasound imaging of atherosclerotic carotid plaque neovascularization: a new surrogate marker of atherosclerosis?” *Vascular Medicine*, vol. 12, no. 4, pp. 291–297, 2007.

[33] D. Staub, A. F. L. Schinkel, B. Coll et al., “Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaques,” *JACC: Cardiovascular Imaging*, vol. 3, no. 7, pp. 761–771, 2010.

[34] S. Partovi, M. Loebe, M. Aschwanden et al., “Contrast-enhanced ultrasound for assessing carotid atherosclerotic plaque lesions,” *American Journal of Roentgenology*, vol. 198, no. 1, pp. W13–W19, 2012.
Submit your manuscripts at http://www.hindawi.com